Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells

Lung Cancer

Volumn 78, Issue 2, 2012, Pages 138-143

  Kikuchi, Junko ^a   Takashina, Taichi ^a   Kinoshita, Ichiro ^b   Kikuchi, Eiki ^a   Shimizu, Yasushi ^b   Sakakibara Konishi, Jun ^a   Oizumi, Satoshi ^a   Marquez, Victor E ^c   Nishimura, Masaharu ^a   Dosaka Akita, Hirotoshi ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

3 Deazaneplanocin A (DZNep); Apoptosis; Epigenetics; EZH2; Non small cell lung cancer; Polycomb group protein; Proliferation

Indexed keywords

3 DEAZANEPLANOCIN A; AGAROSE; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HISTONE H3; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR EZH2;

ANCHORAGE INDEPENDENT GROWTH; APOPTOSIS; ARTICLE; BRONCHUS MUCOSA; CANCER CELL CULTURE; CANCER INHIBITION; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; EPIGENETICS; FIBROBLAST; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; METHYLATION; PRIORITY JOURNAL;

ADENOSINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EPIGENESIS, GENETIC; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; METHYLATION; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE;

EID: 84867401194     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.08.003     Document Type: Article

References (40)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
3. Ringrose L., Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004, 38:413-443.
4. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006, 6:846-856.
5. Cao R., Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004, 14:155-164.
6. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008, 647:21-29.
7. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006, 24:268-273.
8. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
9. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606-11611.
10. Matsukawa Y., Semba S., Kato H., Ito A., Yanagihara K., Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006, 97:484-491.
11. Wagener N., Macher-Goeppinger S., Pritsch M., Husing J., Hoppe-Seyler K., Schirmacher P., et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010, 10:524.
12. Takawa M., Masuda K., Kunizaki M., Daigo Y., Takagi K., Iwai Y., et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 2011, 102:1298-1305.
13. Kikuchi J., Kinoshita I., Shimizu Y., Kikuchi E., Konishi J., Oizumi S., et al. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 2010, 116:3015-3024.
14. McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y., et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012, 109:2989-2994.
15. Karanikolas B.D., Figueiredo M.L., Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate 2010, 70:675-688.
16. Watanabe H., Soejima K., Yasuda H., Kawada I., Nakachi I., Yoda S., et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 2008, 8:15.
17. Ougolkov A.V., Bilim V.N., Billadeau D.D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res 2008, 14:6790-6796.
18. Wagener N., Holland D., Bulkescher J., Crnkovic-Mertens I., Hoppe-Seyler K., Zentgraf H., et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 2008, 123:1545-1550.
19. Wu Z.L., Zheng S.S., Li Z.M., Qiao Y.Y., Aau M.Y., Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010, 17:801-810.
20. Glazer R.I., Hartman K.D., Knode M.C., Richard M.M., Chiang P.K., Tseng C.K., et al. 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun 1986, 135:688-694.
21. Tan J., Yang X., Zhuang L., Jiang X., Chen W., Lee P.L., et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063.
22. Kemp C.D., Rao M., Xi S., Inchauste S., Mani H., Fetsch P., et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 2012, 18:77-90.
23. Crea F., Hurt E.M., Mathews L.A., Cabarcas S.M., Sun L., Marquez V.E., et al. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 2011, 10:40.
24. Hayden A., Johnson P.W., Packham G., Crabb S.J. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat 2011, 127:109-119.
25. Suva M.L., Riggi N., Janiszewska M., Radovanovic I., Provero P., Stehle J.C., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009, 69:9211-9218.
26. Miranda T.B., Cortez C.C., Yoo C.B., Liang G., Abe M., Kelly T.K., et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009, 8:1579-1588.
27. Fiskus W., Wang Y., Sreekumar A., Buckley K.M., Shi H., Jillella A., et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009, 114:2733-2743.
28. Jiang X., Tan J., Li J., Kivimae S., Yang X., Zhuang L., et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008, 13:529-541.
29. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
30. Ramirez R.D., Sheridan S., Girard L., Sato M., Kim Y., Pollack J., et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004, 64:9027-9034.
31. Cozens A.L., Yezzi M.J., Kunzelmann K., Ohrui T., Chin L., Eng K., et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol 1994, 10:38-47.
32. Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998, 90:597-605.
33. Huqun, Ishikawa R., Zhang J., Miyazawa H., Goto Y., Shimizu Y., et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Cancer 2011, 118:1599-1606.
34. Chiang P.K. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol Ther 1998, 77:115-134.
35. Rao M., Chinnasamy N., Hong J.A., Zhang Y., Zhang M., Xi S., et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 2011, 71:4192-4204.
36. Fussbroich B., Wagener N., Macher-Goeppinger S., Benner A., Falth M., Sultmann H., et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 2011, 6:e21651.
37. Tonini T., Bagella L., D'Andrilli G., Claudio P.P., Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 2004, 23:4930-4937.
38. Girard F., Strausfeld U., Fernandez A., Lamb N.J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991, 67:1169-1179.
39. Resnitzky D., Hengst L., Reed S.I. Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol 1995, 15:4347-4352.
40. Fujii S., Fukamachi K., Tsuda H., Ito K., Ito Y., Ochiai A. RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Biochem Biophys Res Commun 2012, 417:1074-1079.